216 related articles for article (PubMed ID: 25918862)
1. Ketorolac salt is a newly discovered DDX3 inhibitor to treat oral cancer.
Samal SK; Routray S; Veeramachaneni GK; Dash R; Botlagunta M
Sci Rep; 2015 Apr; 5():9982. PubMed ID: 25918862
[TBL] [Abstract][Full Text] [Related]
2. DDX3 modulates cisplatin resistance in OSCC through ALKBH5-mediated m
Shriwas O; Priyadarshini M; Samal SK; Rath R; Panda S; Das Majumdar SK; Muduly DK; Botlagunta M; Dash R
Apoptosis; 2020 Apr; 25(3-4):233-246. PubMed ID: 31974865
[TBL] [Abstract][Full Text] [Related]
3. NZ51, a ring-expanded nucleoside analog, inhibits motility and viability of breast cancer cells by targeting the RNA helicase DDX3.
Xie M; Vesuna F; Botlagunta M; Bol GM; Irving A; Bergman Y; Hosmane RS; Kato Y; Winnard PT; Raman V
Oncotarget; 2015 Oct; 6(30):29901-13. PubMed ID: 26337079
[TBL] [Abstract][Full Text] [Related]
4. A Computational Approach with Biological Evaluation: Combinatorial Treatment of Curcumin and Exemestane Synergistically Regulates DDX3 Expression in Cancer Cell Lines.
Rampogu S; Kim SM; Son M; Baek A; Park C; Lee G; Kim Y; Kim GS; Kim JH; Lee KW
Biomolecules; 2020 Jun; 10(6):. PubMed ID: 32512851
[TBL] [Abstract][Full Text] [Related]
5. In vitro anti-cancer activity of doxorubicin against human RNA helicase, DDX3.
Botlagunta M; Kollapalli B; Kakarla L; Gajarla SP; Gade SP; Dadi CL; Penumadu A; Javeed S
Bioinformation; 2016; 12(7):347-353. PubMed ID: 28246464
[TBL] [Abstract][Full Text] [Related]
6. DDX3, a DEAD box RNA helicase with tumor growth-suppressive property and transcriptional regulation activity of the p21waf1/cip1 promoter, is a candidate tumor suppressor.
Chao CH; Chen CM; Cheng PL; Shih JW; Tsou AP; Lee YH
Cancer Res; 2006 Jul; 66(13):6579-88. PubMed ID: 16818630
[TBL] [Abstract][Full Text] [Related]
7. Molecular docking, synthesis, and biological evaluation of 7-azaindole-derivative (7AID) as novel anti-cancer agent and potent DDX3 inhibitor:-an in silico and in vitro approach.
Doneti R; Pasha A; Botlagunta M; Heena SK; Mutyala VVVP; Pawar SC
Med Oncol; 2022 Sep; 39(11):179. PubMed ID: 36048256
[TBL] [Abstract][Full Text] [Related]
8. DEAD-box RNA Helicase DDX3: Functional Properties and Development of DDX3 Inhibitors as Antiviral and Anticancer Drugs.
Kukhanova MK; Karpenko IL; Ivanov AV
Molecules; 2020 Feb; 25(4):. PubMed ID: 32102413
[TBL] [Abstract][Full Text] [Related]
9. FOXO3a reactivation mediates the synergistic cytotoxic effects of rapamycin and cisplatin in oral squamous cell carcinoma cells.
Fang L; Wang H; Zhou L; Yu D
Toxicol Appl Pharmacol; 2011 Feb; 251(1):8-15. PubMed ID: 21092744
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-4 receptor α-based hybrid peptide effectively induces antitumor activity in head and neck squamous cell carcinoma.
Seto K; Shoda J; Horibe T; Warabi E; Ishige K; Yamagata K; Kohno M; Yanagawa T; Bukawa H; Kawakami K
Oncol Rep; 2013 Jun; 29(6):2147-53. PubMed ID: 23563734
[TBL] [Abstract][Full Text] [Related]
11. DDX3, a DEAD box RNA helicase, is deregulated in hepatitis virus-associated hepatocellular carcinoma and is involved in cell growth control.
Chang PC; Chi CW; Chau GY; Li FY; Tsai YH; Wu JC; Wu Lee YH
Oncogene; 2006 Mar; 25(14):1991-2003. PubMed ID: 16301996
[TBL] [Abstract][Full Text] [Related]
12. Low/negative expression of DDX3 might predict poor prognosis in non-smoker patients with oral cancer.
Lee CH; Lin SH; Yang SF; Yang SM; Chen MK; Lee H; Ko JL; Chen CJ; Yeh KT
Oral Dis; 2014 Jan; 20(1):76-83. PubMed ID: 23410059
[TBL] [Abstract][Full Text] [Related]
13. Homology Model-Based Virtual Screening for the Identification of Human Helicase DDX3 Inhibitors.
Fazi R; Tintori C; Brai A; Botta L; Selvaraj M; Garbelli A; Maga G; Botta M
J Chem Inf Model; 2015 Nov; 55(11):2443-54. PubMed ID: 26544088
[TBL] [Abstract][Full Text] [Related]
14. Ezrin Binds to DEAD-Box RNA Helicase DDX3 and Regulates Its Function and Protein Level.
Çelik H; Sajwan KP; Selvanathan SP; Marsh BJ; Pai AV; Kont YS; Han J; Minas TZ; Rahim S; Erkizan HV; Toretsky JA; Üren A
Mol Cell Biol; 2015 Sep; 35(18):3145-62. PubMed ID: 26149384
[TBL] [Abstract][Full Text] [Related]
15. DDX3 as a strongest prognosis marker and its downregulation promotes metastasis in colorectal cancer.
Su CY; Lin TC; Lin YF; Chen MH; Lee CH; Wang HY; Lee YC; Liu YP; Chen CL; Hsiao M
Oncotarget; 2015 Jul; 6(21):18602-12. PubMed ID: 26087195
[TBL] [Abstract][Full Text] [Related]
16. Toward the discovery of novel anti-HIV drugs. Second-generation inhibitors of the cellular ATPase DDX3 with improved anti-HIV activity: synthesis, structure-activity relationship analysis, cytotoxicity studies, and target validation.
Maga G; Falchi F; Radi M; Botta L; Casaluce G; Bernardini M; Irannejad H; Manetti F; Garbelli A; Samuele A; Zanoli S; Esté JA; Gonzalez E; Zucca E; Paolucci S; Baldanti F; De Rijck J; Debyser Z; Botta M
ChemMedChem; 2011 Aug; 6(8):1371-89. PubMed ID: 21698775
[TBL] [Abstract][Full Text] [Related]
17. Level of Murine DDX3 RNA Helicase Determines Phenotype Changes of Hepatocytes In Vitro and In Vivo.
Sergeeva O; Abakumova T; Kurochkin I; Ialchina R; Kosyreva A; Prikazchikova T; Varlamova V; Shcherbinina E; Zatsepin T
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34203429
[TBL] [Abstract][Full Text] [Related]
18. DDX3, a potential target for cancer treatment.
Bol GM; Xie M; Raman V
Mol Cancer; 2015 Nov; 14():188. PubMed ID: 26541825
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of ethyl gallate for its antioxidant and anticancer properties against chemical-induced tongue carcinogenesis in mice.
Mohan S; Thiagarajan K; Chandrasekaran R
Biochem J; 2017 Aug; 474(17):3011-3025. PubMed ID: 28679629
[TBL] [Abstract][Full Text] [Related]
20. Analog sensitive chemical inhibition of the DEAD-box protein DDX3.
Floor SN; Barkovich KJ; Condon KJ; Shokat KM; Doudna JA
Protein Sci; 2016 Mar; 25(3):638-49. PubMed ID: 26650549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
